These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17970614)

  • 21. Aliskiren: a review of its use in the management of hypertension.
    Frampton JE; Curran MP
    Drugs; 2007; 67(12):1767-92. PubMed ID: 17683174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
    Sica D; Gradman AH; Lederballe O; Kolloch RE; Zhang J; Keefe DL
    Clin Drug Investig; 2011 Dec; 31(12):825-37. PubMed ID: 22035463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
    Gradman AH; Traub D
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W; Hermanowicz JM
    Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
    Sealey JE; Laragh JH
    Am J Hypertens; 2007 May; 20(5):587-97. PubMed ID: 17485026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?
    Gaddam KK; Oparil S
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.
    Kwakernaak AJ; Roksnoer LC; Lambers Heerspink HJ; van den Berg-Garrelds I; Lochorn GA; van Embden Andres JH; Klijn MA; Kobori H; Danser AH; Laverman GD; Navis GJ
    PLoS One; 2017; 12(1):e0169258. PubMed ID: 28118402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aliskiren in the management of hypertension.
    Barrios V; Escobar C
    Am J Cardiovasc Drugs; 2010; 10(6):349-58. PubMed ID: 21090828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential benefits of aliskiren beyond blood pressure reduction.
    Weintraub HS; Tran H; Schwartzbard A
    Cardiol Rev; 2011; 19(2):90-4. PubMed ID: 21285669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren.
    Rashid H
    Curr Med Res Opin; 2008 Sep; 24(9):2627-37. PubMed ID: 18687166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety profile of aliskiren: practical implications for clinicians.
    Angeli F; Reboldi G; Poltronieri C; Angeli E; De Filippo V; Crocetti A; Bartolini C; D'Ambrosio C; Verdecchia P
    Curr Drug Saf; 2014; 9(2):106-17. PubMed ID: 24517108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.